These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 30519638)

  • 1. CD5 and CD43 Expression are Associate with Poor Prognosis in DLBCL Patients.
    Huang H; Li Z; Huang C; Rao J; Xie Q; Cui W; Tou F; Zheng Z
    Open Med (Wars); 2018; 13():605-609. PubMed ID: 30519638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexpression of CD5 and CD43 predicts worse prognosis in diffuse large B-cell lymphoma.
    Ma XB; Zhong YP; Zheng Y; Jiang J; Wang YP
    Cancer Med; 2018 Sep; 7(9):4284-4295. PubMed ID: 30019388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis.
    Ma XB; Zheng Y; Yuan HP; Jiang J; Wang YP
    Hum Pathol; 2015 Apr; 46(4):593-9. PubMed ID: 25682152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of the prognostic nutritional index (PNI) in patients with newly diagnosed, CD5-positive diffuse large B-cell lymphoma: A multicenter retrospective study of the Huaihai Lymphoma Working Group.
    Ma S; Zhang B; Lu T; Li D; Li T; Shen Z; He C; Wang Y; Li B; Zhang H; Gu W; Wang C; Ye J; Zhu T; Miao Y; Wang L; Huang S; Liu Q; Sang W;
    Cancer; 2022 Oct; 128(19):3487-3494. PubMed ID: 35932292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathological features of de novo CD5-positive diffuse large B-cell lymphoma].
    Fan Y; Dong L; OUYang BS; Xu HM; Zheng SF; Wang AR; Wang CF
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):448-453. PubMed ID: 32392928
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
    Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
    Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients.
    Yamaguchi M; Nakamura N; Suzuki R; Kagami Y; Okamoto M; Ichinohasama R; Yoshino T; Suzumiya J; Murase T; Miura I; Ohshima K; Nishikori M; Tamaru J; Taniwaki M; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Haematologica; 2008 Aug; 93(8):1195-202. PubMed ID: 18556402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry.
    Cardoso CC; Auat M; Santos-Pirath IM; Rudolf-Oliveira RCM; da Silva JP; Lange BG; Siegel D; de Moraes ACR; Del Moral JAG; Santos-Silva MC
    Cytometry B Clin Cytom; 2018 May; 94(3):451-458. PubMed ID: 28509416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
    Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
    Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features.
    Zukerberg LR; Medeiros LJ; Ferry JA; Harris NL
    Am J Clin Pathol; 1993 Oct; 100(4):373-85. PubMed ID: 8213632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.
    Niitsu N; Okamoto M; Tamaru JI; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Hirano M
    Ann Oncol; 2010 Oct; 21(10):2069-2074. PubMed ID: 20231297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma.
    Kim HY; Jang MA; Kim HJ; Kim SJ; Kim WS; Kim SH
    Blood Res; 2017 Sep; 52(3):193-199. PubMed ID: 29043234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 14. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.
    Chuang WY; Chang H; Shih LY; Wang PN; Chang YS; Lin TL; Hung YS; Yeh CJ; Ueng SH; Tang TC; Kuo MC; Dunn P; Wu JH; Kao HW; Ou CW; Wan YL; Hsueh C
    Virchows Arch; 2015 Nov; 467(5):571-82. PubMed ID: 26369546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.
    Yamaguchi M; Seto M; Okamoto M; Ichinohasama R; Nakamura N; Yoshino T; Suzumiya J; Murase T; Miura I; Akasaka T; Tamaru J; Suzuki R; Kagami Y; Hirano M; Morishima Y; Ueda R; Shiku H; Nakamura S
    Blood; 2002 Feb; 99(3):815-21. PubMed ID: 11806981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of dendritic cell marker CD21 is a positive prognostic factor in diffuse large B-cell lymphoma].
    Yao WK; Wang YP; Peng F; Zheng Y; Zou YB; Gao JN; Liu XL
    Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):818-22. PubMed ID: 23324230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and validation of hub genes in CD5-positive diffuse large B-cell lymphoma.
    Yang M; Niu X; Yang X; Sun Y; Su W; Zhang J; Wu Q; Wang Y; Zhang Q; Ji H
    Exp Biol Med (Maywood); 2023 Sep; 248(17):1469-1478. PubMed ID: 36847415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome and prognostic factors in ocular adnexal lymphoma.
    Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
    Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinicopathologic features and expression of OCT4 protein in testicular diffuse large B cell lymphoma].
    Chen YP; Zhu WF; Chen LF; Lu JP; He TM; Fu WD; Xu CW; Chen G
    Zhonghua Bing Li Xue Za Zhi; 2017 Jun; 46(6):383-387. PubMed ID: 28591984
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma.
    Tang H; Zhou H; Wei J; Liu H; Qian W; Chen X
    Hematology; 2019 Dec; 24(1):446-454. PubMed ID: 31072235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.